Oncology-New York最新文献_第4页

Safeguarding Vulnerability: COVID-19's Impact on Immunocompromised Patients With Cancer. 保护脆弱性：COVID-19对免疫功能低下的癌症患者的影响。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-08-08 DOI: 10.46883/2025.25921049

Viviana Cortiana Ms, Maduri Balasubramanian Md, Jade Gambill Bs, Diksha Mahendru Md, Kennedy Itodo Md, Chandler H Park Md Ms Facp, Yan Leyfman Md

{"title":"Safeguarding Vulnerability: COVID-19's Impact on Immunocompromised Patients With Cancer.","authors":"Viviana Cortiana Ms, Maduri Balasubramanian Md, Jade Gambill Bs, Diksha Mahendru Md, Kennedy Itodo Md, Chandler H Park Md Ms Facp, Yan Leyfman Md","doi":"10.46883/2025.25921049","DOIUrl":"10.46883/2025.25921049","url":null,"abstract":"The COVID-19 pandemic has exposed significant vulnerabilities among patients who are immunocompromised, who remain at increased risk for severe disease despite widespread vaccination in the general population. This commentary reviews insights from Dorry L. Segev's, MD, PhD, keynote lecture at MedNews Week, highlighting reduced vaccine efficacy, prolonged viral shedding, and increased severity of COVID-19 in this population. Emerging strategies such as monoclonal antibody prophylaxis, oral antivirals, personalized vaccine approaches, and T cell-based therapies show promise in mitigating these risks. Additionally, the commentary discusses the implications of hybrid immunity and the potential for within-host viral evolution to generate resistant variants, underscoring the need for targeted genomic surveillance. Ethical considerations are raised regarding the use of advanced oncologic treatments with marginal survival benefits but substantial toxicity in the context of COVID-19 vulnerability. To effectively protect immunocompromised patients, tailored public health measures, dedicated vaccination programs, and integrative lifestyle interventions are required. Synergistic efforts among clinicians, researchers, and policy makers are essential to ensure equitable access to preventive and therapeutic strategies, strengthening health care resilience for vulnerable populations during the ongoing pandemic and beyond.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"null 7","pages":"280-282"},"PeriodicalIF":1.8,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer. 乳腺癌患者GLP-1受体激动剂的使用和体重变化。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-08-08 DOI: 10.46883/2025.25921046

Sherry Shen, Bethina Liu Md, Chad Fanti Md, Maria Bromberg Mph, Yuan Chen PhD, Cassandra Chang, Neil M Iyengar Md

{"title":"GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer.","authors":"Sherry Shen, Bethina Liu Md, Chad Fanti Md, Maria Bromberg Mph, Yuan Chen PhD, Cassandra Chang, Neil M Iyengar Md","doi":"10.46883/2025.25921046","DOIUrl":"10.46883/2025.25921046","url":null,"abstract":"Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis; some breast cancer treatments contribute to postdiagnosis weight gain. We evaluated patients with breast cancer who were prescribed a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with follow-up weight data available. Weights were categorized by time from GLP-1 RA initiation; a linear mixed effects model with a random intercept for baseline weight was used to assess mean weight change at each time point. Among 75 patients, the median age was 52 years (range, 27-74), 62 (86%) were postmenopausal, and 59 (79%) had diabetes. Additionally, 68 (91%) patients had stage 0 to III breast cancer, and 62 (84%) had estrogen receptor-positive disease. The median body mass index (BMI) at baseline was 34 (range, 23-50). The mean weight change was -2.9 kg (95% CI, -4.1 to -1.7) at 6 months and -4.2 kg (95% CI, -5.5 to -2.9) at 12 months; mean weight change at 12 months was -5% (95% CI, -6% to -3%). In univariable and multivariable analyses, age, baseline BMI, diabetes, stage, histology, receptor status, menopausal status, and concurrent endocrine therapy use were not significantly associated with 5% or greater weight loss at 12 months. These results support the development of clinical trials to optimize the use and dosing of GLP-1 RAs for weight loss in patients with breast cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"null 7","pages":"294-296"},"PeriodicalIF":1.8,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment. 揭示Zenocutuzumab的潜力：非小细胞肺癌和胰腺腺癌治疗的突破。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-08-08 DOI: 10.46883/2025.25921048

Sanan Rasheed Mbbs, Umer Farooq Mbbs, Aiman Waheed, Musharaf Khalid Bhutta Mbbs, Adnan Bhat Md, Hamza Nazir Mbbs, Muhammad Hamza Gul, Ayesha Aman Mbbs, Zainab Ibrahim Mbbs, Abdul Baseer Wardak

引用次数: 0

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck. 多西他赛和卡培他滨治疗晚期头颈部鳞状细胞癌的2期研究。

IF 2 4区医学

Oncology-New York Pub Date : 2025-08-08 DOI: 10.46883/2025.25921047

Omar K Abughanimeh Mbbs, Nicole A Shonka Md, Jane Meza PhD, Lynette Smith PhD, Irfan A Vaziri Md, Mehmet Sitki Copur Md, Robin High Mba, Kimberly Shields Bsn Rn, Holly DeSpiegelaere Bsn Rn, Anne Kessinger Md, Apar Kishor Ganti Md Ms

{"title":"A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck.","authors":"Omar K Abughanimeh Mbbs, Nicole A Shonka Md, Jane Meza PhD, Lynette Smith PhD, Irfan A Vaziri Md, Mehmet Sitki Copur Md, Robin High Mba, Kimberly Shields Bsn Rn, Holly DeSpiegelaere Bsn Rn, Anne Kessinger Md, Apar Kishor Ganti Md Ms","doi":"10.46883/2025.25921047","DOIUrl":"10.46883/2025.25921047","url":null,"abstract":"Background: Docetaxel and capecitabine combination have not previously been studied in advanced head and neck squamous cell carcinoma (HNSCC). This study aimed to evaluate the combination's safety and efficacy in this population.Materials and methods: In this single-arm phase 2 trial, patients with advanced HNSCC received docetaxel 75 mg/m 2 intravenously on day 1 in combination with oral capecitabine 800 to 1000 mg/m 2 twice daily from days 1 to 14 of a 3-week cycle, until either progression or toxicity.Results: A total of 14 patients were enrolled in the trial. All participants were men, with a median age of 66 years (range, 47-80). Twelve patients (86%) had received prior chemotherapy. Among the 9 evaluable patients, 1 patient achieved a partial response, 6 had stable disease, and 2 had progression. The median progression-free survival was 4.9 months (95% CI, 1.1-8.2), and the median overall survival was 8.7 months (95% CI, 4.8-17.0). The regimen had an acceptable safety profile. The trial was terminated early due to a change in the standard of care with the introduction of immunotherapy.Conclusions: Despite the trial's early termination, the combination demonstrated a decent disease stability rate with acceptable toxicity. This regimen can be considered for patients with good functional status.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"null 7","pages":"284-290"},"PeriodicalIF":2.0,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Modulation in Sarcoma: Targeting the Tumor Microenvironment. 肉瘤中的免疫调节：靶向肿瘤微环境

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-07-24 DOI: 10.46883/2025.25921045

Viviana Cortiana Ms, Jenna Ghazal BSc, Harshitha Vallabhaneni Bs, Ahmed Hashim Azeez Md, Kennedy Itodo Bs, Chandler H Park Md Ms Facp, Yan Leyfman Md

引用次数: 0

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC. 人工智能在加强非小细胞肺癌精准医疗中的作用。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-06-16 DOI: 10.46883/2025.25921042

Puneet Modgil

引用次数: 0

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection. 结外NK/ t细胞淋巴瘤误诊为肺部感染。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-06-16 DOI: 10.46883/2025.25921043

Dai Hao-Yu, Cao Yi-Wei, Li Shao-Ke, Lin Dong-Liang, Lin Cun-Zhi, Xiao Bao-Hong

引用次数: 0

Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment. 乳腺癌的心脏肿瘤学考虑：风险分层、监测和治疗。

IF 2 4区医学

Oncology-New York Pub Date : 2025-06-16 DOI: 10.46883/2025.25921044

Joseph Wallins, Sara Saravia, Olayiwola Bolaji, Zohaib Shaikh, Anthony Yu

{"title":"Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment.","authors":"Joseph Wallins, Sara Saravia, Olayiwola Bolaji, Zohaib Shaikh, Anthony Yu","doi":"10.46883/2025.25921044","DOIUrl":"10.46883/2025.25921044","url":null,"abstract":"Long-term outcomes of patients with breast cancer have steadily improved due to advances in early detection and cancer therapeutics. Cardiovascular disease (CVD) is a leading cause of non-cancer-related mortality in this population, and this has been attributed to the cardiovascular toxicity of common breast cancer treatments including chemotherapy and radiation as well as shared risk factors between cancer and CVD. Identifying patients at risk of developing treatment-related cardiotoxicities is crucial to inform clinical decisions regarding surveillance, prevention, and management. In this review, we provide a broad overview of the treatment-related cardiotoxicities associated with common breast cancer treatment. We present data on risk-stratification tools for oncologists, including when to refer to a cardiologist, as well as recommendations for cardiovascular testing tailored to individual treatment regimens. Lastly, we review recent trial data on preventive and therapeutic approaches to treatment-related cardiotoxicities, and future directions that may lead to improved cardiovascular outcomes in this population.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"null 5","pages":"188-197"},"PeriodicalIF":2.0,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13107980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease. 诊断特异性分级预后评估在轻脑膜疾病预测中的应用。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-05-12 DOI: 10.46883/2025.25921040

Meghana Kesireddy, Rosalyn Marar, Kaeli Samson, Nicole Shonka

{"title":"Utility of the Diagnosis-Specific Graded Prognostic Assessment for Prognostication in Leptomeningeal Disease.","authors":"Meghana Kesireddy, Rosalyn Marar, Kaeli Samson, Nicole Shonka","doi":"10.46883/2025.25921040","DOIUrl":"10.46883/2025.25921040","url":null,"abstract":"Leptomeningeal disease (LMD) is the spread of cancer cells to the arachnoid mater, pia mater, and cerebrospinal fluid. It occurs in 5% to 10% of solid organ cancers, with higher rates in breast, lung, and melanoma cancers. The prognosis for patients with LMD remains poor, with a median survival of 1.5 months without treatment and 2 to 3 months with treatment, despite advances in cancer treatment. This retrospective study included 64 patients with LMD with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years. Patient characteristics, treatment, and overall survival (OS) data were collected. Statistical analyses included descriptive statistics, log-rank tests, and Cox proportional hazards regression models. The median OS for the 64 patients with LMD was 2.6 months, with no statistically significant differences among cancer types. Though not statistically significant, those with higher DS-GPA scores trended toward longer survival in breast and lung cancer cohorts. Patients with LMD on imaging confined to 1 location (cerebrum, cerebellum, spine, or cranial nerves) and receiving systemic chemotherapy alone also had longer survival. The DS-GPA tool is promising for LMD prognostication and may be strengthened by incorporating imaging and chemotherapy characteristics. Larger, multicenter studies are needed to validate its prognostic utility. Keywords: Leptomeningeal disease, diagnosis-specific graded prognostic assessment, prognosis, overall survival, breast cancer, lung cancer.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"39 4","pages":"141-147"},"PeriodicalIF":1.8,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System. 罕见的原发性中枢神经系统alk阳性间变性大细胞淋巴瘤。

IF 1.8 4区医学

Oncology-New York Pub Date : 2025-05-12 DOI: 10.46883/2025.25921039

Nathalie Soler, Kelly Paz Amador, Alexandra Perez, Camila Solis, Alexander Reyes, Jorge Garcia, Maria Paula Gonzalez Zambrano, Edgar Fabián Manrique Hernández

引用次数: 0